Just a little bit of useless information on an M&A between Biogen and Reata. What peaked my interest was that Biogen paid $7.3b for a company with earning potential of $1.5b in 2030 -
For Biogen, the deal gets the company’s hands on Skyclarys, which carries a sales potential of $1.5 billion in 2030, according to analysts.
Link to full article hereunder for anyone who is interested -
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B | Fierce Pharma
- Forums
- ASX - By Stock
- AVR
- Ann: Exceptional Results in Second Valve-in-Valve Case
Ann: Exceptional Results in Second Valve-in-Valve Case, page-38
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M |
Open | High | Low | Value | Volume |
$15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280 | $15.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 779 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280 | 15.100 |
2 | 96 | 15.020 |
1 | 15 | 15.010 |
2 | 582 | 15.000 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.570 | 779 | 1 |
15.930 | 250 | 1 |
15.940 | 554 | 1 |
15.950 | 848 | 2 |
16.000 | 1250 | 2 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |